Abstract
Autoimmune diseases are a heterogeneous group of disorders and epidemiological studies demonstrate that their incidence is increasing worldwide. It is known that a complex interaction of genetic and environmental factors underlies their complex etiopathogenesis. In the light of the aforegoing the exact molecular key events were difficult to be explored; these represent the leading step to the prevention and treatment of autoimmune disorders.
Novel therapeutic approaches are nowadays under investigation and specific treatments have been preferentially applied in experimental models of disease. New results were brought about and fascinating new pathways for treatment of autoimmunity were launched in the past years.
Nevertheless novel targets for intervention, revealed to be successful in animal models, were not necessarily proven to be successful in humans, therefore were not necessarily introduced in clinical trials.
In this review we present and discuss the results of novel therapeutic approaches and novel experimental strategies including antagonists of cytokines and cytokine receptors, Toll like receptors inhibitors, proteasome inhibitors, antisense oligonucleotides vehicled by nanocarriers, inhibitors of leukocyte migration, kinase inhibitors. We also present the results of ongoing trials in humans that rely on novel biologicals agents. These are presented as applied to organ and non-organ specific autoimmune disorders. In the future, novel therapeutic strategies will also combine different drugs that possibly intervene at different levels in which the immune system may be halted in its function.
Keywords: Etiopathogenesis, autoimmune disorders, cytokines, proteasome, kinases, inhibitors, antisense oligonucleotides, psoriasis, hyperglycemia, liposomes
Current Pharmaceutical Design
Title: Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Volume: 17 Issue: 29
Author(s): Alessandra Fierabracci and Emira Ayroldi
Affiliation:
Keywords: Etiopathogenesis, autoimmune disorders, cytokines, proteasome, kinases, inhibitors, antisense oligonucleotides, psoriasis, hyperglycemia, liposomes
Abstract: Autoimmune diseases are a heterogeneous group of disorders and epidemiological studies demonstrate that their incidence is increasing worldwide. It is known that a complex interaction of genetic and environmental factors underlies their complex etiopathogenesis. In the light of the aforegoing the exact molecular key events were difficult to be explored; these represent the leading step to the prevention and treatment of autoimmune disorders.
Novel therapeutic approaches are nowadays under investigation and specific treatments have been preferentially applied in experimental models of disease. New results were brought about and fascinating new pathways for treatment of autoimmunity were launched in the past years.
Nevertheless novel targets for intervention, revealed to be successful in animal models, were not necessarily proven to be successful in humans, therefore were not necessarily introduced in clinical trials.
In this review we present and discuss the results of novel therapeutic approaches and novel experimental strategies including antagonists of cytokines and cytokine receptors, Toll like receptors inhibitors, proteasome inhibitors, antisense oligonucleotides vehicled by nanocarriers, inhibitors of leukocyte migration, kinase inhibitors. We also present the results of ongoing trials in humans that rely on novel biologicals agents. These are presented as applied to organ and non-organ specific autoimmune disorders. In the future, novel therapeutic strategies will also combine different drugs that possibly intervene at different levels in which the immune system may be halted in its function.
Export Options
About this article
Cite this article as:
Fierabracci Alessandra and Ayroldi Emira, Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases, Current Pharmaceutical Design 2011; 17 (29) . https://dx.doi.org/10.2174/138161211798157586
DOI https://dx.doi.org/10.2174/138161211798157586 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Colon as Target for Drug Delivery
Current Drug Therapy Ubiquitin Ligases as Key Elements for the Modulation of the Immune Response: An Insight in the Pathogenesis of Autoimmunity
Current Rheumatology Reviews Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Vitamin D Receptor as a Drug Discovery Target
Mini-Reviews in Medicinal Chemistry Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD
Current Drug Targets Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry An Update on JAK Inhibitors
Current Medicinal Chemistry Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases
Current Medicinal Chemistry Natural Killer T Cells as Targets for Therapeutic Intervention in Autoimmune Diseases
Current Pharmaceutical Design B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Effect of Recombinant Human Thymosin-α1, an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s
Drug Metabolism Letters Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Cot/Tpl-2 Protein Kinase as a Target for the Treatment of Inflammatory Disease
Current Topics in Medicinal Chemistry The Janus Face of CD4+CD25+ Regulatory T Cells in Cancer and Autoimmunity
Current Medicinal Chemistry The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets